替尔泊肽对比司美格鲁肽在2型糖尿病治疗目标达成中的疗效:SURPASS-2试验事后分析
该事后分析基于SURPASS-2随机3期试验的1879例2型糖尿病成人,比较替尔泊肽(5、10、15 mg)与司美格鲁肽(1 mg)在40周时达成标准与强化治疗目标的情况。结果显示,替尔泊肽所有剂量均增加达标数量,且在HbA1c、体重减轻及强化血压目标上优于司美格鲁肽。
要点
- 替尔泊肽所有剂量均比司美格鲁肽1 mg更多达成标准与强化治疗目标。
- 替尔泊肽15 mg组57%达成≥3个标准目标,司美格鲁肽组为34%。
- 替尔泊肽15 mg组29%达成≥3个强化目标,司美格鲁肽组为8%。
核心结论
- 在2型糖尿病患者中,替尔泊肽相比司美格鲁肽改善治疗目标的达成情况。
- 需要更长期试验确认对长期预后的获益。
研究设计与样本
- SURPASS-2试验的事后分析,该试验为随机3期研究,纳入1879例2型糖尿病成人。
- 参与者随机接受替尔泊肽(5、10或15 mg)或司美格鲁肽(1 mg),分析40周时标准与强化治疗目标的达成情况。
主要发现
- 基线时,19%参与者未达成任何标准目标,59%达成一个,21%达成两个或以上。
- 基线时,58%参与者未达成任何强化目标,38%达成一个,4%达成两个。
- 标准目标方面,司美格鲁肽组34%达成三个或以上目标,替尔泊肽5、10、15 mg组分别为42%、53%、57%。
- 强化目标方面,司美格鲁肽组8%达成三个或以上目标,替尔泊肽5、10、15 mg组分别为15%、20%、29%。
- 替尔泊肽增加达成HbA1c标准目标(<53 mmol/mol [7%],OR 1.50 [95% CI 1.12, 2.00])和强化目标(<48 mmol/mol [6.5%],OR 1.88 [95% CI 1.49, 2.36])的 odds。
关键数值与推荐
- 标准目标:HbA1c <53 mmol/mol [7%],血压 <140/90 mmHg,LDL-胆固醇 <1.8 mmol/l,体重减轻 >10%。
- 强化目标:HbA1c <48 mmol/mol [6.5%],血压 <130/80 mmHg,LDL-胆固醇 <1.4 mmol/l,体重减轻 >15%。
临床怎么用
- 对于需要综合控制血糖、体重和血压的2型糖尿病患者,替尔泊肽可能比司美格鲁肽1 mg更有利于达成治疗目标。
局限性
- 本文为事后分析,需更长期试验确认对长期预后的获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Simultaneous control of HbA1c, lipid profile, BP and body weight is essential for preventing chronic complications of type 2 diabetes. Glucagon-like peptide-1 (GLP-1)-based therapies improve all these variables but whether the dual GLP-1 / glucose-dependent insulinotropic polypeptide (GIP) agonist tirzepatide is superior to semaglutide in attaining therapeutic targets remains unclear. METHODS: We performed a post hoc analysis of the SURPASS-2 trial, a randomised phase 3 study including 1879 adults with type 2 diabetes. Participants were randomised to receive tirzepatide (5, 10 or 15 mg) or semaglutide (1 mg). In this analysis, we compared the effects of tirzepatide vs semaglutide on the attainment of standard (HbA1c <53 mmol/mol [7%], BP <140/90 mmHg, LDL-cholesterol <1.8 mmol/l, >10% weight loss) and intensive (HbA1c <48 mmol/mol [6.5%], BP <130/80 mmHg, LDL-cholesterol <1.4 mmol/l , >15% weight loss) therapeutic targets at 40 weeks. RESULTS: In the SURPASS-2 trial, at baseline, 19% of participants were on target for attaining no standard goals, 59% for one goal and 21% for two or more goals. For intensive therapeutic targets, 58% of participants were on target for attaining zero goals, 38% for one goal and 4% for two goals. All doses of tirzepatide increased the number of achieved standard and intensive targets compared with semaglutide. For standard targets, 34% of participants treated with semaglutide met three or more targets, compared with 42%, 53% and 57% with tirzepatide 5, 10 and 15 mg, respectively. For intensive targets, 8% of participants treated with semaglutide met three or more targets, vs 15%, 20% and 29% with tirzepatide. Regarding specific therapeutic goals, tirzepatide increased the odds of achieving standard and intensive targets for HbA1c (HbA1c <53 mmol/mol [7%], OR 1.50 [95% CI 1.12, 2.00]; HbA1c <48 mmol/mol [6.5%], OR 1.88 [95%CI 1.49, 2.36]) and weight loss (weight loss >10%, OR 2.72 [95% CI 2.14, 3.47]; weight loss >15%, OR 3.86 [95% CI 2.69, 5.55]) and the intensive target for BP (OR 1.45 [95% CI 1.17, 1.81]). CONCLUSIONS/INTERPRETATION: Tirzepatide improves therapeutic target attainment compared with semaglutide in type 2 diabetes. Longer trials are needed to confirm benefits on long-term prognosis. DATA AVAILABILITY: Data for this post hoc analysis was accessed through the Vivli (Center for Global Clinical Research Data) platform ( https://vivli.org ) with the Vivli ID 00009964.
引用
- Neves JS, Leite AR, Vale C, et al. Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial. Diabetologia. 2025. PMID: 41419618. doi:10.1007/s00125-025-06637-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。